

A national survey of attitudes towards and intentions to vaccinate against COVID-19: implications for communications

Martine Stead, Deputy Director^{1*}

Curtis Jessop, Research Director for Longitudinal Surveys²

Kathryn Angus, Research Officer¹

Helen Bedford, Professor of Children's Health³

Michael Ussher, Professor of Behavioural Medicine^{1,4}

Allison Ford, Research Fellow¹

Douglas Eadie, Research Fellow¹

Andy MacGregor, Director of Policy Research²

Kate Hunt, Professor of Behavioural Sciences and Health¹

Anne Marie MacKintosh, Senior Researcher¹

¹Institute for Social Marketing and Health, University of Stirling, Stirling, UK

²NatCen The National Centre for Social Research, London, UK

³Great Ormond Street Institute of Child Health, University College London, London, UK

⁴Population Health Research Institute, St George's University of London, London, UK

*Corresponding author: martine.stead@stir.ac.uk, +44(0)1786 467390, Institute for Social Marketing and Health, University of Stirling, Stirling, FK9 4LA, UK

Abstract

Objectives

To examine public views on COVID-19 vaccination and consider the implications for communications and targeted support.

Design

Cross-sectional study.

Setting

Online and telephone nationally representative survey in Great Britain, January to February 2021.

Participants

4,978 adults. Survey response rate was 84%, among the 5,931 panellists invited.

Main Outcome Measures

Sociodemographic characteristics (age, gender, ethnicity, education, financial status), COVID-19 status, vaccine acceptance, trust in COVID-19 vaccination information sources, perceptions of vaccination priority groups, and perceptions of importance of second dose.

Results

COVID-19 vaccine acceptance (83%) was associated with increasing age, higher level of education and having been invited for vaccination. Acceptance decreased with unconfirmed past COVID-19, greater financial hardship, and non-White British ethnicity; Black/Black British participants had lowest acceptance. Overall, healthcare and scientific sources of information were most trusted. Compared with White British participants, other ethnicities had lower trust in healthcare and scientific sources. Those with lower educational attainment or financial hardship had lower trust in healthcare and scientific sources. Those with no qualifications had higher trust in media and family/friends. While trust was low overall in community or faith leaders it was higher among those with Asian/Asian British and Black/Black British ethnicity compared with White British participants. Views of vaccine prioritisation were mostly consistent with UK official policy but there was support for prioritising additional groups. There was high support for having the second vaccine dose.

Conclusions

Targeted engagement is needed to address COVID-19 vaccine hesitancy in non-White British ethnic groups, in younger adults, and among those with lower education, greater financial hardship and unconfirmed past infection. Healthcare professionals and scientific advisors should play a central role in communications and tailored messaging is needed for hesitant groups. Careful communication around vaccination prioritisation continues to be required.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- The survey was conducted at the start of vaccine rollout giving timely insight into COVID-19 vaccine acceptance/hesitancy and trusted information sources when individuals' decision-making was real rather than hypothetical.
- Results come from a large probability-based sample, representative of adults in Great Britain, which was sufficiently large to examine ethnicity in detail.
- The survey did not include those who are institutionalised (e.g., prisoners), notably difficult to reach populations (e.g., homeless) or those not speaking English (therefore, our ethnic minority sample may underrepresent certain views).
- The survey benefited from a rigorous design, with questionnaire development informed by cognitive interviews conducted with a broad range of individuals.
- A cross-sectional survey cannot infer causality; although variables likely to be important in vaccine acceptance were included, the results are exploratory.

Introduction

Widespread vaccination is likely to be one of the most effective ways of controlling the COVID-19 pandemic, and is central to the UK government's recovery strategy. The UK vaccine programme began in December 2020, prioritising older adults in care homes and their carers, those aged over 80, and frontline health and social-care workers.¹ Administration of first doses of vaccination to the adult population, by decade of age, is to be completed by July 2021. Uncertainty or unwillingness to accept vaccination – 'vaccine hesitancy'² – threatens comprehensive vaccination.^{3,4} Before the introduction of a COVID-19 vaccine, UK surveys reported that 64% to 82% of adults were willing to be vaccinated.⁵⁻¹² Most of these studies used non-probability samples, introducing selection bias and limiting generalisability. Increased vaccine confidence has been reported since vaccination commenced;¹³ possibly due to increased COVID-19 cases and deaths, a further UK lockdown in early 2021, and, increasingly, vaccination becoming the social norm. It is important to examine vaccine acceptance when people are making *active*, rather than *hypothetical*, decisions about vaccination. This also provides insight into potential acceptance of repeat COVID-19 vaccination and boosters.¹⁴

UK uptake has been high (94% of adults surveyed in April reported uptake or intention to accept vaccination),¹³ but there remain concerns about uptake in subpopulations, such as younger adults and some ethnic minorities,¹⁵ giving rise to initiatives such as social media campaigns featuring non-White celebrities.¹⁶ Robust, timely data are needed to identify the characteristics of groups with lower acceptance and the information sources they trust, to inform targeted interventions. It is also important to assess whether attitudes towards COVID-19 vaccination have been affected by specific events and media coverage. Two issues in the UK merit particular attention. First, the government followed recommendations to offer the vaccine to priority groups.¹ If this approach is continued, it is important to examine its acceptability and any implications for communications. Secondly, the government decided, on 30th December 2020, to deviate from recommended protocols for the Pfizer-BioNTech vaccine by extending the interval between doses to up to 12 weeks;¹ this precipitated concerns that it may lead to reduced willingness to be vaccinated or to have a second dose.¹⁷

We conducted a survey in early 2021, using probability sampling, to examine public views on COVID-19 vaccination and consider the implications for communications. During this period most people aged over 80 had been invited to have a vaccine and invitations were being extended to those aged over 70, with other age groups advised they would be invited in the coming months.

Methods

We administered a cross-sectional survey with adults (aged 18+) in Great Britain (GB) in January and February 2021. This paper follows the STROBE Statement for reporting cross-sectional studies.¹⁸

Questionnaire development and testing

The questionnaire was informed by a review of studies on public attitudes towards and experiences of vaccines and COVID-19. Existing measures were adapted^{5,19,20} and new questions developed. The questionnaire was cognitively tested with members of the public to ensure understandability.²¹ Interviews were conducted with 20 individuals recruited by an external fieldwork agency. A purposive sampling approach was employed, with quotas used to ensure people with a mix of genders, ages, parental status, likelihood of accepting a COVID-19 vaccination, and experiences of shielding were recruited. The questionnaire was subsequently revised based on these interviews. Final revisions reflected changes in the UK's vaccine rollout. The questionnaire covered: vaccine acceptance, trust in vaccine information sources, perception of priority groups, COVID-19 status, and perceived importance of a second dose. The questionnaire is provided in Supplementary Material, Methods S1.

Sample and data collection

The target population for the study was adults (18+) living in Great Britain. The survey was administered to the probability-based NatCen Panel,²² recruited from the 2018, 2019, and 2020 waves of the British Social Attitudes survey (BSA), with participants randomly selected from England, Wales and Scotland. All BSA respondents who agreed to join the Panel, had not requested to leave or become inactive were invited to take part, maintaining the random probability design. Data were collected through online and telephone interviews (conducted 14th January to 7th February 2021). Panellists were sent reminders and offered a small financial sum (£5 - £20 depending on interview duration and whether participant had characteristics which are typically under-represented in survey samples) in recognition of their contribution. Participants who did not initially take part online, and for whom a telephone number was available, were followed up by a telephone interviewer and encouraged to take part online or given the opportunity to take part on the telephone. Among 5,931 panellists invited, the survey response rate was 84%, with 4,978 completing it (4,776 online, 202 by telephone). Supplementary Material, Table S1 details overall response rate, accounting for non-response at the panel recruitment stage and panel attrition. Data were weighted for non-response and to be representative of the GB adult population (see Supplementary Material, Methods S2).

Measures

Sociodemographic and other characteristics

Data on age, gender, ethnicity, education, country, urban/rural status, and financial status were obtained from existing information on NatCen panellists. Full details of sub-groups of each variable are provided in Tables 1 and 2. Age was categorised into bands from 18-29 years then ten-year

bands up to 80+. Self-assigned ethnicity was recorded in six categories, and education in five categories according to highest qualification. As indices of multiple deprivation were not available, self-reported financial status was used. COVID-19 status was derived from two items: 1) *“Have you officially been diagnosed with the coronavirus (COVID-19)?”* (yes/no/don’t know); those answering other than ‘yes’ were asked: 2) *“Do you think you have ever had the coronavirus (COVID-19)?”* (yes-definitely/yes-probably/no-probably not/no-definitely not/don’t know).

Vaccine measures

Vaccine acceptance was derived from five items: 1) *“Have you been offered a vaccine for COVID-19?”* (yes/no). Those answering ‘yes’ were asked: 2) *“And have you had that vaccine?”* (yes/no). Participants who had been offered but not yet had the vaccine were then asked: 3) *“And do you intend to have that vaccine?”* (yes/no/not sure). Participants who had not yet been offered the vaccine were asked: 4) *“Would you accept the vaccine for yourself if it is offered to you?”* (yes/no/not sure). Those answering ‘not sure’ were asked: 5) *“If you had to choose, if a COVID-19 vaccine became publicly available and you were offered it, would you accept the vaccine for yourself?”* (yes/no/I’m really not sure). Participants were classed as: ‘Accepted/accepting’ if they answered ‘yes’ to any of items 2, 3, 4, or 5; ‘Uncertain’ if they answered ‘not sure’ to item 3 or ‘I’m really not sure’ to item 5; and ‘Refused/refusing’ if they answered ‘no’ to items 3, 4, or 5.

Trust in information sources was assessed for 13 sources: *“To what extent, if at all, would you trust information about a COVID-19 vaccine from each of the following sources?”* (see Table 3): completely (1); a great deal (2); somewhat (3); very little (4); not at all (5).

Perceptions of vaccine priority groups were assessed across 11 groups (see Table 4): *“Below are some groups that some people say should be the first to be offered a COVID-19 vaccine. For each one, how high a priority do you think it is that they get a COVID-19 vaccine, or do you not think they should be offered the vaccine at all?”*: 1 ‘One of the first’, 5 ‘One of the last’, with an additional option *“They should not be offered a vaccine”*.

Perceived importance of receiving the second dose of the vaccine was assessed with: *“How important, if at all, do you think it is for people to get the second injection of the COVID-19 vaccine?”*: very important (1); fairly important (2); not very important (3); not at all important (4).

Data analysis

Descriptive data, including bivariate analyses, were weighted to be representative of British adult population. Initial bivariate analyses, using chi-square tests, examined correlates of vaccine acceptance and trust in sources of information about COVID-19 vaccination. Multivariate logistic regression was conducted to examine differences in vaccine acceptance controlling for socio-demographic variables, vaccine offer, and COVID-19 status. The dependent variable dichotomised those classed as *accepted/intending to accept* vs *uncertain/refused/intend to refuse*. Age was entered as a categorical variable and the ‘difference’ contrast within SPSS logistic regression was used to test influence of each increasing age group, relative to younger ages (e.g., 30-39 vs 18-29;

80+ vs 18-79) (see Table 2). Sociodemographic variation in trust in information sources was examined using multivariate logistic regressions. For each information source, the dependent variable dichotomised the 5-point scale into trusting *completely or a great deal* vs *somewhat/very little/not at all*. Cases were excluded from the logistic regressions if they had missing data on the dependent or any independent variables. All logistic regressions were conducted on unweighted data as sociodemographic variables were included as control variables. For each information source, logistic regression analysis examined likelihood of trust (completely/a great deal v somewhat/very little/not at all) by sociodemographic characteristics (Supplementary Material, Tables S2-S14). Given the large sample size in this study, the threshold for statistical significance was set at $p < 0.01$. Data were analysed using SPSS v27.

Public and patient involvement

The questionnaire was cognitively tested by members of the public to ensure understandability (see 'Questionnaire development and testing' above).

Results

Sample characteristics

The weighted sample comprised adults aged 18 and over (see Table 1). Over half (52%) were female and 81% were White British. Around two-thirds reported 'living comfortably'/'doing alright', while one in ten rated their financial status as 'quite' or 'very difficult'. Just over two-fifths were educated to degree level or above, while for almost a quarter their highest qualification was A level or equivalent. A minority (12%) had no qualifications. A minority indicated having been diagnosed with COVID-19 (6%); nearly two-thirds thought they probably or definitely had not had COVID-19; 11% were unsure.

Vaccine offer and acceptance

At the time of the survey, 14% (n=716) had been offered the vaccine. Of these, 92% (n=658) had accepted or intended to, 4% (n=29) were uncertain, and 4% (n=29) had refused or intended to refuse.

Among those not yet offered the vaccine, 82% (n=3479) intended to accept, while 11% (n=471) were uncertain and 7% (n=311) indicated they would refuse. Overall, the acceptance level was 83% (n=4137), with 10% (n=502) uncertain and 7% (n=340) refusing.

Multivariate logistic regression, with vaccine acceptance as the outcome variable (accepted/accepting v refused/refusing/uncertain), indicated likelihood of acceptance increased with age (Table 2). For example, those aged 40-49 were more likely than 18-39-year-olds to indicate acceptance (AOR=1.43, 95%CI (1.12, 1.83, $p=0.004$) as were 70-79-year-olds compared with 18-69-year-olds (AOR=3.31, 95%CI (2.22, 4.95), $p < 0.001$). Acceptance was also positively associated with education. Those with at least a degree were three times as likely to indicate acceptance

(AOR=3.03, 95%CI (2.17, 4.23), $p<0.001$) and those educated to A level or equivalent nearly twice as likely (AOR=1.80, 95%CI (1.27, 2.55), $p<0.001$), compared with people without qualifications. Lower acceptance was also associated with financial hardship and ethnicity. For example, compared with those 'living comfortably', people 'finding it very difficult' were much less likely to accept the vaccine (AOR=0.35, 95%CI (0.22, 0.55), $p<0.001$). Compared with White British participants, those from other ethnic groups were less likely to accept the vaccine. Black/Black British participants had the lowest likelihood of accepting (AOR=0.25, 95%CI (0.14, 0.43), $p<0.001$). This is illustrated in the descriptive data too, with 87% of White British participants indicating vaccine acceptance compared with 58% among Black/Black British, 61% among mixed/multiple ethnic groups and 61% among Asian/Asian British.

After controlling for demographic variables, vaccine acceptance was positively associated with having been invited for vaccination (AOR=1.73, 95%CI (1.24, 2.43), $p=0.001$), but negatively associated with COVID-19 status. Compared with those who had 'probably not' or 'definitely not' had COVID-19, those who thought they had 'definitely' or 'probably' had COVID-19 were less likely to indicate acceptance (AOR = 0.40, 95%CI (0.26, 0.60), $p<0.001$ and AOR=0.71, 95%CI (0.56, 0.91), $p=0.006$ respectively). Confirmed diagnosis with COVID-19 was not significantly associated with vaccine acceptance, after controlling for demographic variables.

Trust in information sources

The three most trusted information sources were: the NHS; doctors/nurses/other healthcare professionals; and scientific and medical advisers. These groups were trusted 'completely/a great deal' by around 80% of participants (Table 3). Only 44% trusted the UK government 'completely/a great deal'. The three least trusted sources were celebrities and social media influencers, social media, and faith or community leaders; around two-thirds indicated they would have no trust in each. A majority (61%) indicated they had very little/no trust in the media (e.g., newspapers/magazines/television/radio).

Trust did not differ by gender except for drug companies and the WHO, with females more likely to indicate trust in these sources (Tables S5 and S9 respectively).

Trust was higher among older participants for five sources (doctors/nurses/other healthcare professionals, NHS, UK government, media, and family/friends; Tables S2, S4, S6, S10, S13). For example, trust in the UK government was higher among those aged 50-59 than 18-49-year-olds (Table S6).

Trust varied by education. Compared with those without qualifications, other participants were more likely to trust five sources (doctors/nurses/other healthcare professionals, NHS, scientists, WHO; Tables S2, S4, S8, S9) and less likely to trust another five (drug companies, media, social media, celebrities/social media influencers, family/friends; Tables S5, S10-S13). Compared with those 'living comfortably' participants in more difficult financial situations were less likely to trust the seven sources most closely aligned with scientific or clinical expertise (doctors/nurses/other healthcare

professionals, pharmacists, NHS, drug companies, UK government, scientists, WHO; Tables S2-S6, S8, S9). Similarly, participants from minority ethnic groups were less likely to trust scientific or clinical sources than White British participants (Tables S2-S4, S8, S9). Whilst lack of trust in faith or community leaders was low overall, Asian/Asian British participants were more likely than White British to trust faith/community leaders (AOR=4.82, 95%CI (2.76, 8.42), $p<0.001$) as were Black/Black British participants (AOR=4.52, 95%CI (2.04, 9.99), $p<0.001$) (Table S14).

Views on prioritisation

Nine in ten participants rated healthcare professionals as highest priority for vaccination. Over 70% indicated those with serious health conditions/heightened vulnerability to COVID-19, care home workers and residents, and over 80s should be 'one of the first' to be vaccinated (Table 4). Priority was also given to social care workers, schoolteachers, and those directly working with the public. Over a third considered each of these groups should be 'one of the first' to be vaccinated, and 70% or more rated them in the top two priority levels. People aged under 18 were rated as lowest priority, and 6% considered the vaccine should not be offered to this group.

Importance of second dose

Nearly all participants (96%, $n=4,761$) considered it 'very' or 'fairly important' to receive the second vaccine dose. This increased to 99% ($n=4,096$) amongst those who intended to accept the vaccine.

Discussion

Principal findings

Overall, acceptance was high, with 83% having received or intending to have the vaccine. Acceptance increased with age and education, and if invited for vaccination. It decreased with financial hardship, and among non-White British ethnicities and those with unconfirmed past COVID-19. Clinical and scientific information was most trusted, with sociodemographic differences for different sources. Policy on a second dose and vaccination priority groups¹ was supported.

Comparison with other studies

We confirmed lower acceptance in younger groups;^{6-8,10,11} acceptance was higher if invited for vaccination, a finding observed for other vaccines in other populations,²³ and emphasising the importance of ensuring vaccine invitations are issued, using appropriate language with translations if necessary. Confirmation of lower acceptance in non-White British ethnicities.^{5,6,9,24} is concerning given increased risk of infection and poorer outcomes.²⁵ This lower acceptance has been reported to result from an erosion of trust with health care services as a consequence of past experiences of unethical experimental research conducted among black populations, the lack of participants from ethnic minorities included in health research, particularly vaccine trials, and poor experiences of healthcare.¹⁵ Successful initiatives by primary care health professionals to overcome these barriers have been reported, but they require considerable resources.²⁶ We confirmed lower acceptance in

those with lower educational attainment and greater financial hardship,^{6,8-10,12,27} leaving these groups at risk of infection and increasing likelihood of emergence of variants.²⁸ Gender was not associated with vaccine hesitancy in the analysis reported in this paper, but female gender has been found to be a factor associated with greater COVID-19 vaccine hesitancy in some other studies,^{6,8-10,29} further research is needed to explore whether and why gender may relate to hesitancy.

A novel finding was that there was lower vaccine acceptance among those with unconfirmed but suspected COVID-19. This suggests that prior infection is thought to confer immunity, or that recovery fosters a perception of decreased severity, but further research is needed to explore this relationship. However, past infection does not guarantee protection and people may still be infectious.^{30,31} Messaging should target those with prior infection.

There are other implications for communications. While high acceptance suggests communications are effective, identifying barriers in hesitant groups is a priority for developing interventions.^{3,15,19,32} Trusted information sources are needed. The most trusted were the NHS, healthcare professionals, and scientific and medical advisers. This suggests that healthcare professionals have a central role in promoting vaccination in initiatives and during consultations. That government and media are less trusted has implications for acceptance.^{7,8,27,33} We found particularly low levels of trust in social media and celebrities. However, this does not necessarily mean that they do not influence feelings about vaccination, and, with careful research, they could still play a positive role in communications (for example, initiatives using ethnic minority celebrities and opinion leaders.¹⁶) Such initiatives would need to use pre-testing of messages to ensure they are appropriately tailored to target audiences, while avoiding stereotyping, and would require evaluation of acceptability and effectiveness.

Differences in trust varied by socio-demographics. Compared with White British participants, other ethnicities had lower trust in healthcare and scientific sources. Although trust in faith/community leaders was low, it was higher in Asian and Black British participants, suggesting a role for these leaders.¹⁵ Those with lower educational attainment or financial hardship had lower trust in healthcare and scientific sources. Those with no qualifications had higher trust in media and family/friends. This suggests a need for a mix of sources for these groups. Mainstream media may have a role to play, despite lower trust.²⁷

Reassuringly for further campaigns, for the first time, this study reported that prioritisation was considered acceptable by the general public and there was support for additional prioritisation of schoolteachers and others in direct contact with the public. This is consistent with research suggesting that healthcare workers themselves support the decision to prioritise vaccination for frontline health and social care workers and those at increased risk of vulnerability to infection.³⁴ As planning begins for further vaccination, careful communication regarding prioritisation should continue. We found high support for a second dose, suggesting the UK's decision to extend the

period between doses has not dented public confidence. While the high acceptance rate may suggest that acceptance will be similarly high in future COVID-19 vaccination programmes, this cannot be assumed. The survey was conducted during a period of considerable public anxiety, with rising infection rates and restrictions on many activities including travel. Similar acceptance rates may not be observed in future if the threat is perceived to have receded and society is functioning more normally.

Strengths and limitations

Strengths include the large probability-based nationally representative sample, ability to analyse by ethnicity and surveying during vaccine roll-out. Our findings can be generalised to GB's adult population, however global contexts for COVID-19 and vaccination vary. Although not generalisable to them, the findings are still informative for other countries. The study has limitations. As it is cross-sectional, we cannot infer causality; although we included variables likely to be important in vaccine acceptance, these results are exploratory. Our qualitative studies will deepen understanding of associations. A survey repeated when COVID-19 cases and deaths are low, and without lockdown, might yield different responses. We did not survey individuals who are institutionalised (e.g., prisoners), notably difficult to reach (e.g., homeless), or those not speaking English (therefore, our ethnic minority sample may underrepresent certain views); specific surveys are needed for these groups. We investigated vaccination intention. Actual uptake may be lower, although it is likely that factors associated with intention will influence uptake.

Conclusions

COVID-19 vaccination acceptance is high in GB. Targeted engagement is needed to address hesitancy in non-White British ethnic groups, those with lower education, those younger, those with greater financial hardship and those with unconfirmed but suspected past infection. Healthcare professionals and scientific advisors should lead communications and tailoring is needed. Work is needed to rebuild trust in government information. There is high support for having the second vaccine dose. Views of vaccine prioritisation are mostly consistent with UK official policy but there was support for prioritising additional groups and careful communication around vaccination prioritisation should continue.

Contributors:

MS, CJ, HEB, KH, and AMM conceived the study, supported by AF, DE, and AM. MS, CJ, KA, HB, and AMM designed the questionnaire, supported by MU, AF, DE, AM, and KH. CJ and AMM acquired and analysed the data, which was interpreted by MS, CJ, HB, MU, KH and AMM. MS and AMM drafted the manuscript supported by CJ, HB, MU, and KH. KA, HB, MU, and KH critically revised the article, supported by MS, CJ, AF, DE, AM, and AMM. All authors read the final version of the manuscript and gave approval for it to be published. AMM, CJ, and MS had access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. MS is the guarantor.

Ethics approval:

The study received ethical approval from NatCen's Research Ethics Committee (ID P14307). Participants gave informed consent before taking part.

Transparency declaration:

The lead author and manuscript's guarantor (MS) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned have been explained.

Role of the funding source:

The OPTIMising general public Uptake of a COVID-19 vaccine (OPTIMUM) study was supported by a UK Research & Innovation (UKRI) Ideas to Address COVID-19 award (no. ES/V012851/1). The funder had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. All researchers were independent from the funder and all authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Dissemination to participants and related patient and public communities:

We do not plan to disseminate study results to individual study participants, however findings from the OPTIMUM study will be shared with the public via press releases, social media and interviews, and lay-audience briefing papers.

Data sharing:

After completion of the study, the survey dataset will be deposited in the UK Data Archive.

Competing interests:

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; KH has received another UK Research and Innovation (Economic and Social Research Council) grant on the impact of COVID-19; no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgments:

We thank the questionnaire development and testing and survey and data delivery teams at NatCen for their work on the survey, and Professor Mark Petticrew at the London School of Hygiene & Tropical Medicine for acting as adviser to the study.

References

- 1 UK Government Department of Health and Social Care. Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination, 30 December 2020. Jan 6, 2021. <https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020/joint-committee-on-vaccination-and-immunisation-advice-on-priority-groups-for-covid-19-vaccination-30-december-2020>.
- 2 MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. *Vaccine* 2015;33:4161-4.
- 3 Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. *Vaccine* 2014;32:2150-9.
- 4 Lane S, MacDonald NE, Marti M, Dumolard L. Vaccine hesitancy around the globe: analysis of three years of WHO/UNICEF Joint Reporting Form data—2015–2017. *Vaccine* 2018;36:3861-7.
- 5 Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. *Vaccine* 2020;38:7789-98.
- 6 Freeman D, Loe BS, Chadwick A, Vaccari C, Waite F, Rosebrock L, et al. COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. *Psychol Med* 2020; published online Dec 11. <https://dx.doi.org/10.1017/S0033291720005188>.
- 7 Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. *Nat Med* 2021;27:225-8. <https://doi.org/10.1038/s41591-020-1124-9>.
- 8 Murphy J, Vallières F, Bentall RP, Shevlin M, McBride O, Hartman TK, et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. *Nat Commun* 2021;12:29.
- 9 Robertson E, Reeve KS, Niedzwiedz CL, Moore J, Blake M, Green M, et al. Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study. *Brain Behav Immun* 2021;94:41-50.
- 10 Paul E, Steptoe A, Fancourt D. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. *Lancet Reg Health Eur* 2021;1:100012. <https://doi.org/10.1016/j.lanepe.2020.100012>
- 11 Sherman SM, Smith LE, Sim J, Amlôt R, Cutts M, Dasch H, et al. COVID-19 vaccination intention in the UK: results from the COVID-19 Vaccination Acceptability Study (CoVAccS), a nationally representative cross-sectional survey. *Hum Vaccin Immunother* 2020;26:1-10.
- 12 Williams L, Flowers P, McLeod J, Young D, Rollins L. The Catalyst Project Team. Social patterning and stability of intention to accept a COVID-19 vaccine in Scotland: will those most at risk accept a vaccine? *Vaccines (Basel)* 2021;9:17.

- 13 Office for National Statistics. Coronavirus (COVID-19) latest insights. Apr 16, 2021. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights#vaccinations>. [Accessed Apr 19 2021].
- 14 Mahase E. Covid-19: Booster vaccine to be rolled out in autumn as UK secures 60m more Pfizer doses. *BMJ* 2021;373:n1116.
- 15 Razai MS, Chaudhry UAR, Doerholt K, Bauld L, Majeed A. Covid-19 vaccination hesitancy. *BMJ* 2021;373:n1138.
- 16 Mohdin A. BAME groups urged to have Covid vaccine in UK TV ad campaign. *The Guardian*, Feb 18, 2021. <https://www.theguardian.com/world/2021/feb/18/bame-groups-urged-to-have-covid-vaccine-in-uk-tv-ad-campaign>.
- 17 Sewell HF, Robertson JFR, Stewart M, Kendrick D, Bird SM. Revisiting the UK's strategy for delaying the second dose of the Pfizer covid-19 vaccine. Jan 20, 2021. <https://blogs.bmj.com/bmj/2021/01/20/revisiting-the-uks-strategy-for-delaying-the-second-dose-of-the-pfizer-covid-19-vaccine/>.
- 18 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ*. 2007;335:806-808.
- 19 World Health Organization Regional Office for Europe. Survey Tool and Guidance. Rapid, simple, flexible behavioural insights on COVID-19. Copenhagen: WHO Regional Office for Europe; 2020. https://www.euro.who.int/__data/assets/pdf_file/0007/436705/COVID-19-survey-tool-and-guidance.pdf?ua=1.
- 20 Gallup. Ch 5 Attitudes to vaccines. In: Gallup. Wellcome Global Monitor. How does the world feel about science and health? London: Wellcome Trust, 2019: 104-25. <https://cms.wellcome.org/sites/default/files/wellcome-global-monitor-2018.pdf>.
- 21 Collins D. Cognitive Interviewing Practice. London: SAGE Publications Ltd, 2014.
- 22 Jessop C. The NatCen Panel: developing an open probability-based mixed-mode panel in Great Britain. *Soc Res Pract* 2018;6:2-14. <https://the-sra.org.uk/Common/Uploaded%20files/Social%20Research%20Practice%20Journal/social-research-practice-journal-issue-06-summer-2018.pdf>.
- 23 Jacobson Vann JC, Jacobson RM, Coyne-Beasley T, Asafu-Adjei JK, Szilagyi PG. Patient reminder and recall interventions to improve immunization rates. *Cochrane Database Syst Rev* 2018;1:CD003941.
- 24 Thorneloe R, Wilcockson H, Lamb M, Jordan CH, Arden M. Willingness to receive a COVID-19 vaccine among adults at high-risk of COVID-19: a UK-wide survey. *PsyArXiv* 2020; published online Jul 20. <https://psyarxiv.com/fs9wk> (preprint).
- 25 Mathur R, Rentsch CT, Morton CE, Hulme WJ, Schultze A, MacKenna B, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit

- admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. *Lancet*. 2021;397:1711-24.
- 26 Mahase E. Covid-19 vaccines: GPs boost uptake by calling patients and teaming up with community groups *BMJ* 2021;374:n2093.
- 27 Allington D, McAndrew S, Moxham-Hall V, Duffy B. Coronavirus conspiracy suspicions, general vaccine attitudes, trust and coronavirus information source as predictors of vaccine hesitancy among UK residents during the COVID-19 pandemic. *Psychol Med* 2021; published online April 12. <https://doi.org/10.1017/s0033291721001434>
- 28 Sah P, Vilches TN, Moghadas SM, Fitzpatrick MC, Singer BH, Hotez PJ, et al. Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants. *EClinicalMedicine* 2021;35:100865.
- 29 Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. *EClinicalMedicine*. 2020;26:100495. <https://doi.org/10.1016/j.eclinm.2020.100495>
- 30 Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *Lancet* 2021;397:1204-12.
- 31 Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet* 2021;397:1459-69.
- 32 Lockyer B, Islam S, Rahman A, Dickerson J, Pickett K, Sheldon T, et al. Understanding COVID-19 misinformation and vaccine hesitancy in context: Findings from a qualitative study involving citizens in Bradford, UK. *Health Expect* 2021; published online May 4. <https://dx.doi.org/10.1111/hex.13240>
- 33 Williams L, Gallant AJ, Rasmussen S, Brown Nicholls LA, Cogan N, et al. Towards intervention development to increase the uptake of COVID-19 vaccination among those at high risk: Outlining evidence-based and theoretically informed future intervention content. *Br J Health Psychol* 2020;25:1039-54.
- 34 Manby R, Dowrick A, Karia A, Maio L, Buck C, Singleton G, et al. Healthcare workers' perceptions and attitudes towards the UK's COVID-19 vaccination programme. *medRxiv* 2021; published online Mar 31. <https://doi.org/10.1101/2021.03.30.21254459> (preprint).

Table 1 Sample characteristics

	Unweighted		Weighted	
	n	%	n	%
Age				
18-29	464	9.4	824	16.7
30-39	772	15.6	852	17.3
40-49	848	17.1	806	16.3
50-59	904	18.3	867	17.6
60-69	1011	20.4	711	14.4
70-79	773	15.6	657	13.3
80+	178	3.6	218	4.4
Gender				
Male	2136	42.9	2402	48.3
Female	2830	56.9	2567	51.6
Other	10	0.2	7	0.1
Ethnicity				
White British	4261	86.3	3999	81.2
Any other White background	319	6.5	335	6.8
Mixed or multiple ethnic groups	64	1.3	100	2.0
Asian or Asian British	164	3.3	306	6.2
Black or Black British	67	1.4	101	2.1
Other	62	1.3	81	1.6
Country				
England	4369	87.9	4291	86.3
Scotland	390	7.8	442	8.9
Wales	212	4.3	237	4.8
Urban/rural status[#]				
Urban	3789	76.2	4006	80.6
Rural	1182	23.8	965	19.4
Highest educational qualification				
Degree or equivalent, and above	2503	50.4	2077	41.8
A levels or vocational level 3 or equivalent and above, but below degree	1005	20.2	1131	22.8
Other qualifications below A levels or vocational level 3 or equivalent	788	15.9	838	16.9
Other qualification	256	5.2	304	6.1
No qualifications	416	8.4	618	12.4
Subjective Financial Status				
Living comfortably	1552	31.2	1289	26.0
Doing alright	2028	40.8	2035	40.9
Just about getting by	975	19.6	1132	22.8
Finding it quite difficult	271	5.5	337	6.8
Finding it very difficult	142	2.9	175	3.5
COVID-19 Status				
Diagnosed with COVID-19	241	4.8	294	5.9
Think definitely had COVID-19	140	2.8	172	3.5
Think probably had COVID-19	710	14.3	755	15.2

Think probably not had COVID-19	1945	39.1	1880	37.8
Think definitely not had COVID-19	1393	28.0	1305	26.2
Don't know if had COVID-19	547	11.0	566	11.4

England and Wales, based on Office for National Statistics (ONS) definition of urban as population greater than 10,000. Scotland based on Scottish Government definition of urban as population greater than 3,000.

Table 2 Association between vaccine acceptance and sociodemographic variables – (a) bivariate results and (b) multivariate logistic regression.

	(a) Bivariate associations between vaccine acceptance and socio-demographics % Accepted/Intend to Accept (weighted) χ^2 test for differences by demographics				(b) Logistic regression of vaccine acceptance 1 = Accepted/Intend to Accept (4294), 0 = Uncertain/Refused/Intend to Refuse (600)				
	n	%	χ^2 (df)	P	N	AOR*	95% CI Lower	95% CI Upper	P
Gender			2.154 (2)	.341					0.085
Male	2012	83.8			2097	ref			
Female	2117	82.5			2788	0.82	0.67	0.99	0.036
Other	5	71.4			9	0.47	0.09	2.45	0.369
Age			274.733 (6)	<.001					<.001
18-29	613	74.4			459	ref			
30-39 v 18-29	618	72.5			761	0.89	0.66	1.20	.448
40-49 v 18-39	640	79.3			835	1.43	1.12	1.83	.004
50-59 v 18-49	745	85.9			896	1.92	1.49	2.46	<.001
60-69 v 18-59	659	92.7			1003	3.21	2.37	4.34	<.001
70-79 v 18-69	629	95.7			763	3.31	2.22	4.95	<.001
80+ v 18-79	209	95.9			177	2.19	0.92	5.21	.078
Education/Highest qualification			56.056 (4)	<.001					<.001
No qualifications	495	80.1			411	ref			
Degree or equivalent and above	1811	87.2			2454	3.03	2.17	4.23	<.001
A levels / Vocational level 3 or equivalent	909	80.4			990	1.80	1.27	2.55	<.001
Other qual'ns below A level / Voc level 3	694	82.7			784	1.50	1.05	2.15	.026
Other qualification	223	73.4			255	0.90	0.58	1.39	.632
Financial Status			168.660 (4)	<.001					<.001
Living comfortably	1162	90.1			1533	ref			
Doing alright	1749	86.0			1998	0.89	0.69	1.15	.383
Just about getting by	848	74.9			959	0.52	0.39	0.69	<.001
Finding it quite difficult	261	77.2			266	0.74	0.50	1.10	.139
Finding it very difficult	111	63.4			138	0.35	0.22	0.55	<.001
Country			3.171 (2)	.205					.326
England	3581	83.5			4302	ref			
Scotland	356	80.5			384	0.82	0.59	1.13	.220
Wales	192	81.0			208	0.80	0.51	1.26	.345
Urban/rural			34.517 (1)	<.001					
Urban	3266	81.5			3729	ref			
Rural	863	89.4			1165	1.28	1.00	1.65	.051
Ethnicity			246.434 (5)	<.001					<.001
White British	3482	87.1			4226	ref			
Any other white background	254	75.8			318	0.55	0.40	0.76	<.001
Mixed or multiple ethnic groups	62	61.4			62	0.39	0.21	0.71	.002
Asian or Asian British	188	61.4			161	0.41	0.28	0.61	<.001
Black or Black British	59	58.4			67	0.25	0.14	0.43	<.001
Other	59	72.8			60	0.42	0.23	0.79	.007
Whether been offered vaccine			45.924 (1)	<.001					
No	3479	81.6			4227	ref			
Yes	658	91.9			667	1.73	1.24	2.43	.001
COVID-19 Status			72.865 (4)	<.001					<.001

Think probably or definitely <u>not</u> had COVID-19	2741	86.1			3288	ref			
Diagnosed with COVID-19	218	74.4			240	0.89	0.60	1.33	.575
Think definitely had COVID-19	118	68.2			140	0.40	0.26	0.60	<.001
Think probably had COVID-19	598	79.1			691	0.71	0.56	0.91	.006
Don't Know if had COVID-19	462	81.5			535	0.73	0.55	0.97	.031
					Hosmer & Lemeshow $\chi^2= 7.444$, $df=8$, $p=0.490$. Final model $\chi^2=497.429$, $df=29$, $p<0.001$ Nagelkerke = 0.184 Cases correctly classified: 88.1%. 84 cases excluded due to missing data on one or more independent variables.				

* adjusted for all other variables in the model, AOR, adjusted odds ratio; ref, reference category; 95%CI, 95% confidence interval

Table 3 Trust in potential sources of information on COVID-19 vaccine

Source:	Level of Trust (trust completely [1]...not at all [5])										Mean	Std Dev
	Completely (1)		A great deal (2)		Somewhat (3)		Very little (4)		Not at all (5)			
	n	%	n	%	n	%	n	%	n	%		
The NHS	2084	41.9	1902	38.3	701	14.1	155	3.1	127	2.5	1.86	0.95
Doctors, nurses or other healthcare professionals	1918	38.6	2092	42.1	714	14.4	154	3.1	90	1.8	1.87	0.90
Scientific and medical advisers	1798	36.2	2101	42.3	792	15.9	160	3.2	121	2.4	1.94	0.93
The World Health Organisation (WHO)	1313	26.4	2016	40.6	1070	21.6	310	6.2	256	5.1	2.23	1.07
Pharmacists	999	20.1	1973	39.7	1434	28.8	341	6.9	226	4.5	2.36	1.02
The UK Government	654	13.2	1542	31.1	1739	35.1	614	12.4	402	8.1	2.71	1.10
Scottish Govt/Welsh Assembly ^a	118	17.4	189	27.9	207	30.5	88	13.1	75	11.1	2.72	1.21
Drug companies who manufacture vaccines	406	8.2	1064	21.4	2065	41.6	771	15.5	661	13.3	3.04	1.11
Family and friends	343	6.9	876	17.6	2230	44.9	977	19.7	542	10.9	3.10	1.04
The media (e.g. newspapers, magazines, television, radio)	86	1.7	302	6.1	1567	31.5	1433	28.9	1580	31.8	3.83	1.00
Faith or community leaders	131	2.6	124	2.5	619	12.5	827	16.7	3264	65.7	4.40	0.98
Social media (e.g. Twitter, Facebook, Instagram etc)	65	1.3	69	1.4	506	10.2	1267	25.5	3056	61.6	4.45	0.83
Celebrities and social media influencers	60	1.2	71	1.4	493	9.9	1175	23.6	3170	63.8	4.47	0.82

Base: All participants (weighted). Missing cases range from n=3 to n=27. ^aBase: all participants in Scotland or Wales, n=679 (weighted). List order was randomised for each participant.

Table 4 Views on priority groups for vaccination: who should be first and last groups vaccinated

	Should not be offered		Priority of being offered ^a										Mean ^b	Std Dev
			One of the first (1)		(2)		(3)		(4)		One of the last (5)			
	n	%	n	%	n	%	n	%	n	%	n	%		
Doctors, nurses and other healthcare professionals	33	0.7	4472	90.0	280	5.6	83	1.7	15	0.3	83	1.7	1.17	0.63
People with serious health conditions which mean they are vulnerable to COVID-19	35	0.7	4017	80.9	671	13.5	129	2.6	35	0.7	77	1.6	1.27	0.69
Care home workers	36	0.7	3926	79.0	683	13.8	197	4.0	58	1.2	66	1.3	1.31	0.72
Residents in a care home	47	0.9	3593	72.4	734	14.8	337	6.8	123	2.5	131	2.6	1.47	0.93
People aged 80 or over	49	1.0	3613	72.9	706	14.2	304	6.1	118	2.4	168	3.4	1.48	0.96
Social care workers	33	0.7	2683	54.0	1348	27.2	683	13.8	143	2.9	75	1.5	1.70	0.92
Schoolteachers	47	0.9	2098	42.2	1621	32.6	886	17.8	223	4.5	94	1.9	1.90	0.97
People with jobs that involve direct contact with members of the public	45	0.9	1864	37.5	1603	32.3	1157	23.3	228	4.6	70	1.4	1.99	0.96
People aged 31-50	43	0.9	154	3.1	614	12.4	2096	42.2	1486	30.0	568	11.4	3.35	0.95
People aged 18-30	102	2.0	123	2.5	289	5.8	943	19.0	1375	27.7	2130	42.9	4.05	1.05
People aged under 18	282	5.7	148	3.0	253	5.1	657	13.3	831	16.8	2788	56.2	4.25	1.08

Base: All participants (weighted). ^a Missing cases range from n=11 to n=21. ^b Excludes 'should not be offered', missing cases range from n=45 to n=301. List order was randomised for each participant.